Lisa Mosconi on menopause, the female brain, and Alzheimer's risk in women

This is our independent, journal-club summary of JJ Virgin’s conversation with neuroscientist Lisa Mosconi, PhD. We distill what was said, separate solid evidence from the speaker’s opinion, and align her study claims against the actual research. You can and should read the full official transcript yourself.

One note up front. The episode page carries a May 2025 timestamp, but the conversation itself is older: Mosconi describes her book The XX Brain as “coming out in March,” and that book published in March 2020. So the science she discusses reflects roughly the 2019-2020 picture. We checked her specific numbers against the primary sources below.

Who is talking and why it matters to you

Mosconi directs the Women’s Brain Initiative at Weill Cornell and is associate director of its Alzheimer’s Prevention Clinic. Her whole career has centered on one question that most longevity podcasts skip: why do women’s brains age differently from men’s, and what does that mean for dementia? She came to it personally. Her grandmother and both of that grandmother’s sisters developed dementia while their brother did not, a pattern that pushed her toward studying who is at risk and whether anything can be done.

For an APOE4 carrier, especially a woman, this fills a real gap. About two of three people living with Alzheimer’s are women, and the genetics hit women harder in midlife. A large meta-analysis found that women carrying a single APOE4 copy faced roughly a fourfold higher risk of developing Alzheimer’s between ages 65 and 75, and female E4 carriers accumulate more Alzheimer’s pathology than male carriers. Mosconi’s work is squarely about that window. We cover the underlying genetics in how APOE4 affects the brain and APOE4 and Alzheimer’s risk, and the female-specific picture in APOE4, women, and sex differences.

Menopause as a brain event, not just an ovary event

The most useful reframe in the episode is that menopause is neurological. Mosconi argues the classic symptoms (hot flashes, night sweats, insomnia, depression, brain fog, “cognitive slippage”) do not start in the ovaries. They start in the brain, because estrogen is what she calls a master regulator there: it helps activate neurons, supports their energy supply, and is involved in plasticity and immune function. When estrogen falls during the transition, the brain has to readjust, and for some women that readjustment goes badly.

That estrogen matters for brain energy and function is established neuroscience. Where she goes further, and labels it her own view, is the leap to Alzheimer’s. In her words, “for women, menopause could be really a trigger for Alzheimer’s disease.” Read that as a hypothesis she holds strongly and has built imaging research around, not as proven cause and effect. She is explicit that perimenopause is a vulnerable window, not a verdict, and that most women going through it will not develop Alzheimer’s.

She also floats a newer idea: that men and women may take different routes to the disease, more vascular in men (driven by blood-pressure and vessel problems) and more metabolic in women (driven by blood sugar, weight, cholesterol, thyroid). She flags this as something that had emerged only recently at the time. It is a plausible, still-unsettled direction, not a conclusion to bank on.

The numbers she cites, checked against the studies

This is a conversational interview, so it trades in fewer hard figures than a typical research podcast. Three claims carry actual numbers, and they are worth pinning down.

Trans fats and the brain. Mosconi calls trans fats the single worst fat you can eat and says they are “associated with over 30 percent higher risk of heart disease and twice the risk of dementia in women, especially those younger than 65.” The heart-disease half checks out cleanly. A 20-year follow-up of about 78,000 women in the Nurses’ Health Study found trans fat intake raised coronary heart disease risk by 33 percent (relative risk 1.33), and the effect was strongest in women under 65 (relative risk 1.50). The dementia half is shakier. The cleanest primary study on trans fats and dementia, the Hisayama Study, measured trans fat in the blood of about 1,600 older Japanese adults and found the highest levels carried roughly a 50 to 75 percent higher risk of dementia and Alzheimer’s. Real, but not a doubling, and not a women-specific or under-65 finding. So treat “twice the risk of dementia in women” as her stronger synthesis from her book, not what the primary dementia evidence shows. The honest version: trans fats look genuinely bad for both heart and brain, with the firmest number being about a third more heart disease in women.

Berries. She says eating at least three servings of berries a week keeps women’s brains “younger by two to three years.” This matches the primary research well. A large study within the Nurses’ Health Study (Devore and colleagues) found women eating more strawberries and blueberries had cognitive aging delayed by up to about 2.5 years. Her characterization is accurate, with the serving count rounded a bit. It is an observational link, which can show association without proving cause, but the direction is consistent with the broader flavonoid literature.

Fish and menopause timing. She notes eating fish once or twice a week is associated with later menopause, while smoking is the number one cause of early menopause. Both are reasonable summaries of observational data. The fish-and-menopause-timing link in particular is association, not established cause.

On omega-3s, it is worth connecting this to the carrier-specific wrinkle other guests have raised: APOE4 carriers may get less DHA into the brain and may need a higher dose or a better-absorbed form. Mosconi does not get into that here, but we cover it in omega-3, DHA, and APOE4. Her food groups also overlap heavily with the Mediterranean and MIND diets, which have the strongest dietary evidence for brain aging.

Hormone therapy: where she is careful

When JJ Virgin asks whether the real treatment for menopause-driven brain changes is bioidentical hormone replacement, Mosconi does not take the bait. She calls it a very good question, then says the debate is “more with the scientific community,” that there are different schools of thought, and that “it depends.” Her own lean: if a woman has an Alzheimer’s predisposition that menopause appears to activate, “I would want to really treat.” That is her clinical opinion on a genuinely unsettled question, and she frames it that way.

This is the responsible position. Whether hormone therapy lowers dementia risk depends heavily on timing, formulation, and who is treated, and the evidence is mixed rather than settled. If you are weighing this, our deep dive on APOE4, menopause, and HRT lays out what the trials actually show and the carrier-specific nuances, which matter because the decision is not one-size-fits-all.

Fair warning

A few honest caveats.

This is a short, friendly interview built partly around the launch of Mosconi’s book The XX Brain. That is not a knock, but it means the framing leans toward a clear, marketable story (menopause as the key to the female Alzheimer’s gap) more than a hedged research talk would. The book’s commercial purpose is the conflict to keep in mind.

The episode never mentions APOE4 by name in the part of the conversation about her own research, and it does not get into carrier-specific dosing or risk numbers. JJ Virgin asks about “the ApoE testing,” and Mosconi confirms APOE is a genetic risk factor that raises risk without causing the disease, then pivots to the broader point that 20 to 30 other genes also nudge risk, mostly through inflammation, and that lifestyle can push back. So the carrier relevance here is the female-brain and menopause framing, not a tailored E4 protocol.

The diet advice, while sound, is mostly general healthy-eating guidance (antioxidants, omega-3s, avoid processed food and trans fats) reframed for the brain. It is good advice. It is not Alzheimer’s-specific proof, and the episode does not pretend the food list is a treatment.

One claim drifts past the evidence: the “twice the risk of dementia” trans fat figure, which the primary dementia study does not support as a sex-specific doubling. And the central thesis, that menopause triggers Alzheimer’s in susceptible women, remains her well-argued hypothesis, not established cause and effect.

Bottom line for a carrier

The durable, well-supported messages: women make up about two-thirds of Alzheimer’s cases and APOE4 hits women harder in midlife, so the menopause transition is a real window to pay attention to your brain, not just your hot flashes. Estrogen genuinely matters for brain energy and function. Trans fats are worth cutting (the firmest number is about a third more heart disease in women, especially under 65). Berries, fish, and plant sources of phytoestrogens are low-risk, evidence-aligned additions, and they overlap with the Mediterranean and MIND diets that have the best brain-aging track record.

Hold these as hypotheses, not conclusions: that menopause itself triggers Alzheimer’s, that women’s path is specifically metabolic, and that hormone therapy prevents dementia. Those are live questions, and the right move is to bring them, with your own numbers and family history, to a clinician who knows you. If a positive APOE4 result is weighing on you, our piece on coping after a positive APOE4 result may help, and reading a study like a skeptic is a good companion for any of the figures above.

---

This is general information, not medical advice, and it is our distillation rather than the guest’s exact words. Read the full official transcript before acting on anything here, and talk to a doctor who knows your history.